University of Tokyo

Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.

Mutation, structural variant, and expression data for up to three dozen TNBCs led to a subset of tumors with homologous recombination changes.

The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

Japanese researchers uncovered recurrent DUX4 fusions in adolescent or young adult cases of B-cell acute lymphoblastic leukemia, along with other new ALL fusions.

Filamentous fungi are used in a variety of industrial processes and genome editing could increase enzyme yield and efficiency.